Synaptic dysregulation in a mouse model of GRIN2D developmental and epileptic encephalopathy
- PMID: 40200555
- PMCID: PMC12588716
- DOI: 10.1093/brain/awaf125
Synaptic dysregulation in a mouse model of GRIN2D developmental and epileptic encephalopathy
Abstract
Gain-of-function (GoF) variants in the GRIN2D gene, encoding the GluN2D subunit of the N-methyl-D-aspartate receptor (NMDAR), cause a severe developmental and epileptic encephalopathy (DEE) characterized by intractable seizures, hypotonia and neurodevelopmental delay. We generated mice carrying the GoF V664I variant, orthologous to V667I, which is present in ∼25% of GRIN2D-DEE patients. Heterozygous mutant mice demonstrate behavioural, neuroanatomical and electrophysiological abnormalities. Lethal convulsive seizures are observed beginning at postnatal Day 17. As adults, heterozygotes display abundant and prolonged runs of spike-wave discharges (SWD) that often persist for minutes. The SWD epochs consist of different populations, differentiated by frequency and association with time-locked behavioural arrest. V664I mutant neurons have enlarged presynaptic terminals and increased synaptic distance. Functional analysis reveals increased inhibitory synaptic activity without changes in NMDAR decay kinetics or presynaptic plasticity in CA1 neurons, and analysis of hippocampal local field potentials shows a 1.5-fold increase in evoked responses and a 1.7-fold increase in action potential generation. Notably, expression of V664I in GABAergic interneurons, but not excitatory forebrain neurons, is sufficient to recapitulate the severe electroclinical phenotype. Altogether, our studies show that altered NMDAR function in inhibitory neurons plays a prominent role in DEE associated with GRIN2D GoF variants, suggesting that targeted genetic treatment may represent a path forward to successful therapeutic intervention.
Keywords: GRIN2D; epilepsy; neurodevelopment; seizures; synaptic dysfunction.
© The Author(s) 2025. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
Conflict of interest statement
S.F.T. is a co-inventor of Emory-owned intellectual property. S.F.T. is a member of the SAB for Sage Therapeutics, Eumentis Therapeutics, Neurocrine, the GRIN2B Foundation, the CureGRIN Foundation, and CombinedBrain. S.F.T. is a consultant for GRIN Therapeutics. S.F.T. is cofounder of NeurOp, Inc. and Agrithera. T.T.S is a consultant for BioMarin Pharmaceuticals.
References
-
- Tsien JZ. Linking Hebb’s coincidence-detection to memory formation. Curr Opin Neurobiol. 2000;10:266–273. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
